Suganto Sutjipto
Overview
Explore the profile of Suganto Sutjipto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Callahan S, Wonganan P, Obenauer-Kutner L, Sutjipto S, Dekker J, Croyle M
J Virol Methods
. 2007 Dec;
148(1-2):132-45.
PMID: 18160141
Inactivated viruses are important tools for vaccine development and gene transfer. 8-Methoxypsoralen (8-MOP) and long-wavelength ultraviolet irradiation (LWUVI) inactivates many viruses. Toxicity limits its use in animals and humans. Toxicological...
2.
Howe J, Pelka P, Antelman D, Wilson C, Cornell D, Hancock W, et al.
Virology
. 2005 Oct;
345(1):220-30.
PMID: 16246392
Production of E1-deleted adenovirus (rAd) vectors requires complementation by E1A and E1B functions provided by the production cell line. The two cell lines most commonly used for production of rAd...
3.
Machemer T, Engler H, Tsai V, Lee S, Cannon-Carlson S, Voloch M, et al.
Mol Ther
. 2005 Jul;
12(2):254-63.
PMID: 16043097
Intravascular administration of recombinant adenovirus (rAd) in cancer patients has been well tolerated. However, dose-limiting hemodynamic responses associated with suppression of cardiac output have been observed at doses of 7.5...
4.
Sutjipto S, Ravindran S, Cornell D, Liu Y, Horn M, Schluep T, et al.
Hum Gene Ther
. 2005 Feb;
16(1):109-25.
PMID: 15703494
As virus vectors for gene therapy approach the goal of successful clinical treatment, it is increasingly necessary for the product to be fully characterized. Empty capsids are perhaps the main...